Please sign in with your existing account details.
Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.
Privacy statement - Terms and conditions
Forgotten your password?
You have exceeded the maximum number of login attempts for this email address and your account has been locked. An email has been sent to member of Browne Jacobson's web team and some one will be contacting you over the next two working days with details of how to change your password.
Are you sure you want to remove this item from you pinned content?
Reports of schools entering poor value equipment leasing arrangements highlight an issue that is now more relevant than ever as academies take responsibility for their own contracts.
Many contract problems stem from unclear terms and conditions, such as complex cash-back arrangements provided by intermediaries (often agreed verbally with nothing in writing). This makes cash back arrangements difficult to pursue and can and has left schools on the hook for the full, often inflated charges. For example when the intermediary ceases trading, leaving the school unable to recover cash-back payments directly from the finance company.
Schools should compare the cost of purchasing the equipment from an independent supplier, and against more straightforward arrangements without cash-back. Particular care should always be taken over cash-back schemes and other complex proposals. It may in any event be a good time for schools - particularly academies directly responsible for these issues - to consider their approach to procuring private sector contracts.
With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.
View blog
The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.
Our top tips for supporting transgender and non-binary pupils.
On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.
Partner
Select which mailings you would like to receive from us.
Sign up